Perspective · 5 Nov 2025
Research articlePublished 2018
Efficacy and Safety of Escitalopram in First Episode of Major Depressive Disorder - A Tertiary Care Indian Center Experience
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Context: Major Depressive Disorder (MDD) is the most prevalent psychiatric illness and escitalopram is one of the most commonly used selective serotonin reuptake inhibitors (SSRI) for its treatment. Aim: To study efficacy and safety of escitalopram in patients with first episode of MDD. Materials and methods: This was a prospective, open label, eight weeks follow-up study. Eighty-four patients with first episode of MDD were selected using simple random sampling. Depression was diagnosed using DSM-5 diagnostic criteria for MDD. Montgomery-Asberg Depression Rating Scale (MADRS) was used to assess the severity of depression. Clinical Global Impression Severity (CGI-S) and Clinical Global Impression Improvement (CGI-I) were used to measure illness severity and global improvement. The Antidepressant Side-Effect Checklist (ASEC) was used to measure adverse reactions to antidepressants. Results: The mean of MADRS total score at baseline was 32.08 which was decrease in subsequent follow up and at 8-week score was 11.24. 77% of patients responded (≥50% or more reduction of MADRS total score) and 64.9% remitted (≤12 score of MADRS) at 8 weeks. 22.9% of patients reported side effects during the 8-week treatment. 94.2% of patients got significant improvement with 10 mg dose of escitalopram. The common side effects were constipation (5.4%), nausea (5.4%), dry mouth (4.1%) and yawning (4.15%). Conclusion: Escitalopram treatment was efficacious and well tolerated in patients with first episode of MDD. Nearly two third patients achieved remission at the end of eight week.
Subjects
Mental Health and PsychologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Depression and Anxiety.
Opinion · 5 Nov 2025
Protective Factors Promoting Resilience Against Depression and Anxiety
Perspective · 5 Nov 2025
Innovative Strategies for Effective Anxiety Management in Clinical Practice
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Depression and Anxiety
- SubjectMental Health and Psychology
- BylineArticles whose byline prints “Mayur G Patel”
- BylineArticles whose byline prints “Vishal K Patel”
- BylineArticles whose byline prints “Deepak S Tiwari”
- BylineArticles whose byline prints “Viral R Shah”
- BylineArticles whose byline prints “Dhruv S Patel”
- BylineArticles whose byline prints “Nirav B Chanpa”
